{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:11Z","timestamp":1793091251517,"version":"4.5.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,22]]},"DOI":"10.1093\/infdis\/jiy382","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T17:29:05Z","timestamp":1531589345000},"page":"S127-S133","source":"Crossref","is-referenced-by-count":40,"title":["Herpes Zoster Vaccines"],"prefix":"10.1093","volume":"218","author":[{"given":"Anthony L","family":"Cunningham","sequence":"first","affiliation":[{"name":"Westmead Institute for Medical Research"},{"name":"University of Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"key":"key\n\t\t\t\t20180922075203_CIT0001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2013.00171","article-title":"Immunosenescence and novel vaccination strategies for the elderly","volume":"4","author":"Dorrington","year":"2013","journal-title":"Front Immunol"},{"key":"key\n\t\t\t\t20180922075203_CIT0002","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJM199111213252101","article-title":"The protective efficacy of polyvalent pneumococcal polysaccharide vaccine","volume":"325","author":"Shapiro","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0003","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","article-title":"Antibody response to influenza vaccination in the elderly: a quantitative review","volume":"24","author":"Goodwin","year":"2006","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0005","first-page":"1268","article-title":"Zoster vaccine","volume-title":"Vaccines","author":"Levin","year":"2017","edition":"7th ed"},{"key":"key\n\t\t\t\t20180922075203_CIT0006","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0007","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0008","volume-title":"Zostavax (zoster vaccine live) product insert","author":"Merck & Co","year":"2014"},{"key":"key\n\t\t\t\t20180922075203_CIT0009","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0011","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0012","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20180922075203_CIT0013","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0014","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0015","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.23412","article-title":"Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax) in individuals aged \u226570 years: a randomized study of a single dose vs. two different two-dose schedules","volume":"9","author":"Vesikari","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180922075203_CIT0016","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1473-3099(16)00133-X","article-title":"Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial","volume":"16","author":"Beals","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0018","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.578","volume-title":"Varicella zoster virus (VZV) cell-mediated immunity 3 years after the administration of zoster vaccine to septuagenarians immunized 10 years previously [poster I715]","author":"Weinberg","year":"2016"},{"key":"key\n\t\t\t\t20180922075203_CIT0019","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10 year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1086\/514077","article-title":"Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine","volume":"176","author":"Redman","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0022","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0023","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180922075203_CIT0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t20180922075203_CIT0026","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0027","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res"},{"key":"key\n\t\t\t\t20180922075203_CIT0029","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/0264-410X(94)00073-V","article-title":"Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine","volume":"13","author":"Vafai","year":"1995","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0030","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0031","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0032","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0033","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0034","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0035","first-page":"153","article-title":"Recombinant subunit vaccines: potentials and constraints","volume":"121","author":"Clark","year":"2005","journal-title":"Dev Biol (Basel)"},{"key":"key\n\t\t\t\t20180922075203_CIT0036","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0037","first-page":"1","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","author":"Schwarz","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180922075203_CIT0038","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0039","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180922075203_CIT0040"},{"key":"key\n\t\t\t\t20180922075203_CIT0041","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0042","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults >50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial","volume":"13","author":"Godeaux","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180922075203_CIT0043","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180922075203_CIT0044","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180922075203_CIT0045","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1128\/JVI.01020-10","article-title":"Characterization of the host immune response in human ganglia after herpes zoster","volume":"84","author":"Gowrishankar","year":"2010","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180922075203_CIT0046","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/JVI.03445-13","article-title":"Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia","volume":"88","author":"Steain","year":"2014","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180922075203_CIT0047","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180922075203_CIT0048","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t20180922075203_CIT0049","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180922075203_CIT0050","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180922075203_CIT0051","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0052","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/infdis\/jix482","article-title":"Immunogenicity and safety of the HZ\/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine","volume":"216","author":"Grupping","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0053","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180922075203_CIT0054","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180922075203_CIT0055","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180922075203_CIT0056","volume-title":"Zostavax (frozen) [package insert]","author":"Merck & Co Inc","year":"2006"},{"key":"key\n\t\t\t\t20180922075203_CIT0057","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"J Am Geriatr Soc"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/suppl_2\/S127\/25823549\/jiy382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T20:58:49Z","timestamp":1571605129000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/suppl_2\/S127\/5105942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":57,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2018,9,22]]},"published-print":{"date-parts":[[2018,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy382","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,1]]},"published":{"date-parts":[[2018,9,22]]}}}